Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab

Romero‐Maté, Alberto; García‐Donoso, Carmen; Hernández‐Núñez, A.; Martínez‐Morán, C.; Moreno-Torres, Amalia; Borbujo-Martínez, J.

doi:10.5070/d3231033677

Cited by 13 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of six patients were enrolled with a median age of 47 years 31–59 and diagnosed as Hurley III stage HS, who failed to or contraindication of adalimumab. After 12‐week treatment of ustekinumab, 50% of the patients achieved Hidradenitis Suppurativa Clinical Response (HiSCR) 30 …”

Section: Resultsmentioning

confidence: 99%

Off‐label uses of ustekinumab

Li³

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Ustekinumab (brand name Stelara ® ) is a human interleukin-12 and -23 antagonist and has been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. This review aims to synthesize and interpret the literature evaluating the off-label uses of ustekinumab. We performed searches in PubMed and ClinicalTrials.gov for clinical trials, observational studies, case series, and case reports evaluating label uses of ustekinumab.Studies evaluated the efficacy of ustekinumab for the following conditions: other types of psoriasis (expect plaque psoriasis and psoriatic arthritis), pityriasis rubra pilaris, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, et al.

show abstract

Section: Resultsmentioning

confidence: 99%

Off‐label uses of ustekinumab

Li³

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…There have been individual case reports on the treatment of CLE and SLE with other biologicals such as ustekinumab, an interleukin‐12 and interleukin‐23 antibody. Inhibition of the IL12/23/17 pathway may however induce (cutaneous) LE as well [107–114]. Based on the results of a phase II study, apremilast also shows efficacy in CLE [115].…”

Section: Treatmentmentioning

confidence: 99%

“…Currently, rituximab has not been approved for treating SLE in any country. There has been only a small number of case reports and clinical studies [102] on the use of rituximab in CLE [99,103] [107][108][109][110][111][112][113][114]. Based on the results of a phase II study, apremilast also shows efficacy in CLE [115].…”

Section: Rituximabmentioning

confidence: 99%

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

Worm

Zidane

Eisert³

et al. 2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Topical treatment Topical glucocorticoidsClass 2-4 topical glucocorticoids are the treatment of choice for cutaneous lupus erythematosus (CLE). A randomized, controlled study has shown that fluocinonide 0.05 % is more effective than hydrocortisone 1 % [1]. Class 4 topical glucocorticoids are indicated for lesions on the capillitium, the palms of the hands/soles of the feet, and for hyperkeratotic lesions, covered by a foil/hydrocolloid dressing where required. Strictly intralesional injections of triamcinolone acetonide may be considered in individual cases, and this may be repeated after 4-6 weeks as needed. Side effects with use over longer periods of time are a limiting factor, so either short-term use over a period of several weeks, or interval treatment is recommended. Recommendation Strength AgreementTopical glucocorticoids are recommended for treating circumscribed CLE lesions.

show abstract

“…Über die Anwendung weiterer Biologika, wie beispielsweise Ustekinumab, einem Antikörper gegen Interleukin‐12 und Interleukin‐23, wurden einzelne Fallberichte bezüglich der Behandlung eines CLE und SLE veröffentlicht. Die Blockade der IL12/23/17‐Achse kann allerdings auch einen (kutanen) LE auslösen [107–114]. Aufgrund der Ergebnisse einer Phase‐2‐Studie zeigt auch Apremilast eine Wirksamkeit beim CLE [115].…”

Section: Weitere Immunmodulatorenunclassified

S2k‐Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen

Worm

Zidane

Eisert

et al. 2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Topische Glukokortikoide der Klasse 2-4 sind die Mittel der Wahl bei kutanem Lupus erythematodes (CLE). In einer randomisierten klinischen Studie wurde gezeigt, dass Fluocinonid 0,05 % wirksamer ist als Hydrokortison 1 % [1]. An Capillitium, Handflächen/Fußsohlen beziehungsweise hyperkeratotischen Herden sind topische Glukokortikoide Klasse 4, gegebenenfalls auch unter Folie/Hydrokolloidverband, indiziert. In Einzelfällen ist eine streng intraläsionale Injektion von Triamcinolonacetonid zu erwägen (gegebenenfalls Wiederholung nach 4-6 Wochen). Die Verwendung wird durch die Nebenwirkungen bei längerer Applikation limitiert, so dass hier kurzfristige Anwendungen über mehrere Wochen beziehungsweise Intervalltherapien zu empfehlen sind. Empfehlung Stärke ZustimmungTopische Glukokortikoide werden zur Behandlung umschriebener CLE-Läsionen empfohlen.

show abstract

Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab

Abstract: A 52-year-old woman had a 28-year history of DLE, which exhibited clinically with disfiguring, erythematous and scaly plaques with atrophic scars of the face, neck, and upper back (Figure 1). DLE was histopathologically confirmed (Figure 2).

Cited by 13 publications

References 12 publications

Off‐label uses of ustekinumab

Off‐label uses of ustekinumab

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

S2k‐Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes – Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen

Contact Info

Product

Resources

About